High
4.3018
Open
4.250
VWAP
4.25
Vol
88.49K
Mkt Cap
113.16M
Low
4.150
Amount
376.27K
EV/EBITDA(TTM)
--
Total Shares
26.01M
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
Show More
Valuation Metrics
The current forward P/E ratio for Liminatus Pharma Inc (LIMN.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Liminatus Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
LIMN News & Events
Events Timeline
2025-07-28 (ET)
2025-07-28
07:34:53
Liminatus Pharma to launch 'American BNB Strategy' subsidiary
2025-07-25 (ET)
2025-07-25
08:36:36
Liminatus Pharma evaluates formation of digital asset investment vehicle
2025-07-24 (ET)
2025-07-24
08:45:25
Liminatus Pharma entered into engagement agreement with Digital Offering
Sign Up For More Events
Sign Up For More Events
News
8.5
07-28NewsfilterLiminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
8.5
07-25NewsfilterLiminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
8.5
07-24NewsfilterLiminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
Sign Up For More News
People Also Watch
TSLA
Tesla Inc
341.354
USD
+0.15%
NVDA
NVIDIA Corp
180.230
USD
-1.60%
META
Meta Platforms Inc
782.460
USD
-0.95%
AMZN
Amazon.com Inc
224.360
USD
+1.30%
AAPL
Apple Inc
232.030
USD
+1.04%
MSFT
Microsoft Corp
524.600
USD
-0.88%
AVGO
Broadcom Inc
306.110
USD
-2.15%
WMT
Walmart Inc
101.860
USD
-1.70%
XOM
Exxon Mobil Corp
106.320
USD
+0.18%
ORCL
Oracle Corp
246.630
USD
-2.85%
FAQ
What is Liminatus Pharma Inc (LIMN) stock price today?
The current price of LIMN is 4.21 USD — it has decreased -3.22 % in the last trading day.
What is Liminatus Pharma Inc (LIMN)'s business?
What is the price predicton of LIMN Stock?
What is Liminatus Pharma Inc (LIMN)'s revenue for the last quarter?
What is Liminatus Pharma Inc (LIMN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Liminatus Pharma Inc (LIMN)'s fundamentals?
How many employees does Liminatus Pharma Inc (LIMN). have?